Press release

Evonik unveils PERACLEAN® 22 CW for meat and poultry processing applications

PARSIPPANY, N.J., March 22, 2017

Evonik Corporation’s PERACLEAN® 22 CW was recently approved for use in meat and poultry processing by the United States Department of Agriculture (USDA) and Food and Drug Administration (FDA).

PERACLEAN® 22 CW, a peracetic acid, is an environmentally friendly, antimicrobial agent approved for use in a number of intervention points including both online and offline reprocessing spray, wash, rinse, chiller or scald, and other process water for whole or cut meat and poultry carcasses.

“With these approvals, PERACLEAN® 22 CW is now fully able to participate in the meat and poultry processing industries,” said Florian Lyon, Manager, Business Development, Active Oxygens, North America for Evonik. “This stable, chlorine-free solution produces zero harmful byproducts and breaks down into carbon dioxide, oxygen and water.”

PERACLEAN® 22 CW is also OMRI and Kosher certified and meets all USDA standards when used as directed for applications up to 2,000 ppm. This product helps control bacteria and reduce bacterial contamination. PERACLEAN® 22 CW is also process-friendly and requires no rinsing, is non-foaming, and non-corrosive to stainless steel.

Follow us on Twitter and Facebook.

Downloads

Contact

Robert Brown

Contact

  • Phone:  +1 973 929-8812
  • E-mail:  E-mail
  • Company information

    Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world with more than 35,000 employees. In fiscal 2016 the enterprise generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2,165 billion.

  • Disclaimer

    In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.